Last reviewed · How we verify
Nalidixate (NALIDIXIC ACID)
Nalidixate, also known as Nalidixic Acid, is a small molecule drug that targets the 5-hydroxytryptamine receptor 2B. Originally developed in the 1960s, it is an off-patent, generic medication used to treat bacterial urinary infections. It was first approved by the FDA in 1964 and has a high bioavailability of 96%. Nalidixate is classified as a nalidixic acid drug and is manufactured by multiple generic manufacturers. As an off-patent medication, it is no longer protected by active patents.
At a glance
| Generic name | NALIDIXIC ACID |
|---|---|
| Drug class | nalidixic acid |
| Target | 5-hydroxytryptamine receptor 2B |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1964 |
Approved indications
- Bacterial urinary infection
Common side effects
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |